Poor prognosis acute myelogenous leukemia: 3—biological and molecular biological changes during remission induction therapy-Reference-Cited by-同舟云学术

Poor prognosis acute myelogenous leukemia: 3—biological and molecular biological changes during remission induction therapy

Published:2001-09 Issue:9 Volume:25 Page:783-791
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Devemy E,Li B,Tao M,Horvath E,Chopra H,Fisher L,Nayini J,Creech S,Venugopal P,Yang J,Kaspar C,Hsu W.-T,Preisler H.D

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia;Preisler;Leuk. Res.,1992

2. Regrowth resistance as a likely significant contributor to treatment failure in drug sensitive neoplastic diseases;Preisler;Cancer Invest.,1997

3. The relationship between tumor proliferation and the response of malignant disease to cytotoxic therapy: Some lessons learned from cell cycle studies;Preisler;Cancer Res. Ther. Control,1998

4. Poor prognosis acute myelogenous leukemia: 1-Response to treatment with high dose cyarabine/mitoxantrone/ethyol (Amifostine);Preisler;Leuk. Res.,2000

5. Poor prognosis acute myelogenous leukemia: 2-Biological and molecular biological characteristics and treatment outcome;Li;Leuk. Res.,2000

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia;Journal of Hematology & Oncology;2018-01-05

2. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?;Current Opinion in Hematology;2016-03

3. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “3 + 7” induction regimen for acute myeloid leukemia;American Journal of Hematology;2015-11-17

4. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant;Leukemia & Lymphoma;2010-06

5. Resistance to Ara-C Up-Regulates the Activation of NF-.KAPPA.B, Telomerase Activity and Fas Expression in NALM-6 Cells;Biological and Pharmaceutical Bulletin;2007